Suprarenin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suprarenin

Quick Facts

Property Description
Active ingredient Epinephrine (Adrenaline)
Form Sterile Solution for Injection (Parenteral)
Pharmacological class Non-selective Adrenergic Receptor Agonist
Common use Rapid physiological support during acute crises
Origin Endogenous compound (Catecholamine Derivative)

What Type of Medicine is Suprarenin (Epinephrine)?

Suprarenin is a pharmaceutical preparation defined by its active ingredient, Epinephrine, which is scientifically and commonly known as Adrenaline. It is a single-active ingredient product belonging to the definitive pharmacological class of adrenergic receptor agonists, specifically acting as a non-selective sympathomimetic agent that engages both alpha- and beta-receptors. The active substance, Epinephrine, is fundamentally an endogenous compound—a potent catecholamine derivative and hormone that is naturally synthesized by the human body to act as a crucial neurotransmitter. As a therapeutic product, it is most commonly supplied as a sterile solution for injection, a parenteral liquid preparation, differentiating it from oral or inhaled forms of related medicines. The substance exhibits potent alpha and beta agonist activity, which initiates rapid systemic effects.


Suprarenin's General Purpose as a Rapid Systemic Agent

The general purpose of Suprarenin is to provide immediate, powerful physiological support to restore stability during acute, life-threatening circulatory or respiratory crises. Its utility as a rapid systemic agent stems from its comprehensive action across the body's vital systems. By acting as a potent vasoconstrictor, it tightens blood vessels to increase systemic vascular resistance and raise low blood pressure. Simultaneously, it exerts a cardiotonic effect by increasing the myocardial force of contraction and the heart rate, while also providing bronchial smooth muscle relaxation to open constricted airways. This immediate, balanced response facilitates the stabilization of critical functions during episodes requiring the swift management of systemic distress. The drug is characterized by a rapid onset, which is utilized when systemic collapse is imminent.

Regulatory References

  1. NIH Epinephrine StatPearls
  2. MedlinePlus Epinephrine Injection

What side effects are possible with Suprarenin?

Possible side effects and safety information

Suprarenin (Epinephrine) is a potent sympathomimetic agent whose official safety profile reflects its comprehensive action on the cardiovascular and nervous systems, as documented in regulatory labeling. The most commonly documented adverse reactions typically involve the Nervous System (e.g., anxiety, restlessness, tremor, weakness, dizziness, headache) and Cardiac System (e.g., palpitations, pallor). Nausea and vomiting are also listed among the frequent reactions.


Serious Adverse Reactions and Systemic Complications

Official regulatory information documents several clinically significant events. Serious adverse reactions include life-threatening cardiac arrhythmias (such as ventricular fibrillation), myocardial infarction, and the precipitation or aggravation of angina pectoris. Rapid increases in blood pressure are documented, which may lead to cerebral hemorrhage or stroke. Pulmonary edema is also noted as a potential serious complication.

As a parenteral solution, the drug carries local risks. Extravasation (leakage outside the vein) can result in local tissue necrosis. Furthermore, rare reports of serious skin and soft tissue infections, including necrotizing fasciitis, have been documented at the injection site.


Population-Specific Safety Considerations

Regulatory labeling notes that certain populations may be at an increased risk of adverse reactions. Older adults are more sensitive to the drug's effects and are at greater risk of cerebral hemorrhage from rapid blood pressure elevation. Patients with pre-existing heart disease have an increased risk of ventricular arrhythmias and aggravated angina. The labeling also states that the medicine may cause fetal harm, and pregnant women may be at a greater risk of adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Suprarenin overdose is officially documented as presenting with signs of acute cardiovascular overstimulation. Manifestations commonly include severe hypertension, profound tachycardia, palpitations, acute pulmonary oedema, severe headache, and high anxiety or restlessness. The most serious, life-threatening outcomes cited in regulatory documents are ventricular fibrillation, cardiac arrest, myocardial necrosis, and the risk of cerebral hemorrhage secondary to the hypertensive crisis.


Required Emergency Actions

Immediate medical attention is required for any suspected overdosage. Call emergency services or contact a Poison Control Center immediately. Official guidance states that administration of more than two sequential doses of Epinephrine is a threshold requiring direct medical supervision. Management is limited to symptomatic and supportive treatment, including the use of counteracting agents, such as alpha-blockers, for severe pressor effects. Mandatory hospital monitoring of blood pressure and ECG is required for observation. Elderly patients are officially noted as being at a higher risk for severe effects, including cerebrovascular events.

Therapeutic Uses of Suprarenin

What Suprarenin Treats: Main Uses and Benefits

Suprarenin is a synthetic preparation of epinephrine (adrenaline), a hormone and neurotransmitter naturally produced by the body. In medical settings, it is utilized for its rapid effect on the cardiovascular and respiratory systems, particularly during acute, life-threatening situations.

Primary Medical Uses

  • Cardiopulmonary Resuscitation: One of the primary applications of Suprarenin is during cardiac arrest. It is used to help restart heart activity and maintain blood flow to vital organs by increasing systemic vascular resistance and improving perfusion pressure.
  • Anaphylaxis Treatment: It is the first-line intervention for severe allergic reactions (anaphylaxis). In these cases, it works to reverse low blood pressure, reduce swelling of the airways, and decrease the release of inflammatory mediators.
  • Severe Asthmatic Attacks: For patients experiencing acute, severe bronchial constriction that does not respond to standard inhalers, Suprarenin can help relax the muscles in the airways to facilitate breathing.
  • Local Vasoconstriction: In surgical or dental procedures, Suprarenin is often used as an additive to local anesthetics. It constricts blood vessels at the injection site, which helps prolong the numbing effect and reduces localized bleeding.

Therapeutic Benefits

  • Rapid Onset of Action: When administered intravenously or intramuscularly, the effects are nearly instantaneous, which is critical in emergency medicine.
  • Vasoconstriction: By narrowing the blood vessels, it helps raise blood pressure during distributive or cardiogenic shock.
  • Bronchodilation: It acts on the receptors in the lungs to quickly open narrowed air passages, providing relief from acute respiratory distress.
  • Restoration of Cardiac Rhythm: In cases of heart failure or arrest, it can help stimulate the heart muscle and restore a functional rhythm.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Suprarenin (Epinephrine)

The population eligibility for Suprarenin, a form of Epinephrine, is determined by official government labeling, with a primary distinction between life-threatening emergencies and other medical situations.

Eligibility Scope

Classification Statement of Regulatory Status
Use in Acute Crisis The medicine is generally not restricted by absolute contraindications when used to treat life-threatening conditions such as anaphylaxis, as the need for immediate intervention is paramount.
Absolute Contraindications None are typically listed for emergency use. Contraindications, such as hypersensitivity to the drug or non-anaphylactic shock, are generally reserved for non-emergent applications.

Population and Condition Restrictions

Official labeling requires caution when administering Suprarenin to patients with certain pre-existing conditions. These include cardiac arrhythmias, coronary artery disease, hyperthyroidism, or severe hypertension, due to the risk of aggravating these conditions. Use is established for adults and across the full pediatric range, though dosing is weight-dependent. Elderly (geriatric) patients are identified as a population requiring increased caution due to a greater risk of adverse reactions. Similarly, pregnancy is a conditional restriction, as the drug may cause fetal harm, but treatment should not be withheld if necessary to save the mother's life. Caution is also advised during lactation and in patients with renal impairment.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Suprarenin (Epinephrine)

Interaction Scope

Category Official Regulatory Documentation Summary
Medicinal product categories with documented interactions Sympathomimetics, Beta-blockers, Alpha-blockers, Antihypertensives, Potassium-depleting diuretics, Tricyclic Antidepressants (TCAs), MAO Inhibitors (MAOIs), COMT Inhibitors, Cardiac glycosides, and Phenothiazine antipsychotics.
Mechanistic basis of interactions Primarily pharmacodynamic interactions (e.g., counteracting or potentiating pressor effects). Metabolic inhibition (MAO and COMT inhibition) is documented to enhance pressor effects.
Timing-based interaction rules No explicit mandatory timing or separation rules for co-administration are documented in the available government regulatory text.
Population-specific interaction notes Elderly patients are documented as being at greater risk of developing adverse reactions when Epinephrine is administered parenterally.
Interaction-related restrictions Co-administration of Phenothiazine antipsychotics is formally restricted when treating hypotension caused by Epinephrine, due to the documented risk of reversing the pressor effect.

Official Interaction Statements

  • Potentiation and Hypertension Risk: MAO Inhibitors, TCAs, and COMT Inhibitors are officially documented to potentiate the pressor effects, with the potential for resulting in severe, prolonged hypertension.
  • Antagonism of Effects: Alpha-blockers and certain Antihypertensives are documented to counter the pressor effects of Epinephrine.
  • Arrhythmia Risk: Beta-blockers, certain anesthetics (halogenated), and cardiac glycosides are explicitly listed as increasing the arrhythmogenic potential.
  • Hypokalemic Potentiation: Potassium-depleting diuretics and Corticosteroids are stated to potentiate the hypokalemic effects of Epinephrine.

Connection to the overall interaction profile

The regulatory interaction profile is primarily defined by pharmacodynamic effects that modify Epinephrine’s cardiovascular actions and by metabolic inhibition that increases exposure. Official documents formally define constraints by categorizing substances based on documented outcomes such as enhanced pressor effects, reduced efficacy, or heightened risk of cardiac arrhythmias.

Mechanism of Action

Suprarenin (Epinephrine) acts as a non-selective agonist to the entire suite of adrenergic receptors (alpha1, beta1, beta2), directly mimicking the sympathetic nervous system's command signals. This immediate, comprehensive engagement of G protein-coupled receptor pathways is central to its mechanism of action.

Dual Activation of Cardiac and Vascular Pathways

This domain covers the simultaneous activation of beta1 receptors in the heart and alpha1 receptors on the vasculature. beta1 agonism enhances the force and rate of myocardial contraction, while alpha1 agonism induces widespread smooth muscle constriction in blood vessels. The resulting physiological consequence is a rapid increase in cardiac output coupled with a rise in systemic vascular resistance and blood pressure.

Airway and Inflammatory Cascade Modulation

This mechanism involves the beta2 receptors located on the bronchial smooth muscle and various immune cells. beta2 receptor activation triggers a pathway that leads to the relaxation of bronchial smooth muscle (bronchodilation) and inhibits the immediate release of inflammatory mediators like histamine from immune cells. This targeted pathway adjustment engages molecular sequences responsible for modulating activity in the respiratory and immune systems.

Dosage and Administration Information

How Suprarenin is Used in Clinical Practice

Suprarenin (Epinephrine) is a sterile solution administered via parenteral routes, meaning it is delivered via injection. The required route of administration, strength, and schedule are defined by the specific clinical situation.


Acute and Intermittent Use

For immediate intervention during an acute systemic crisis, the medicine is typically administered as an Intramuscular (IM) injection, or alternatively, Subcutaneous (SC). The standard adult dosage for this purpose is 0.3 mg to 0.5 mg of the 1 mg/mL solution. The preferred injection site is the anterolateral aspect of the thigh. This dose may be repeated every 5 to 10 minutes as necessary.

Dosing for the pediatric population is weight-based, requiring a calculated dose of 0.01 mg/kg (up to a maximum of 0.3 mg), administered via the IM route.


Continuous Critical Care Use

When utilized for sustained physiological support, such as for the management of hypotension in shock, Suprarenin is administered as a continuous Intravenous (IV) infusion. This administration requires specialized care, as the concentrated 1 mg/mL solution must first be diluted in a 5% dextrose-containing solution. The infusion rate is individualized and is titrated (adjusted) according to the patient's measured blood pressure response, commonly within a range of 0.05 mcg/kg/min to 2 mcg/kg/min. Upon stabilization, the continuous infusion dose must be weaned incrementally rather than abruptly stopped.

Recent Clinical Evidence

Research evidence / Overview of Studies for Suprarenin

Evidence for Use in Severe Allergic Reactions (Anaphylaxis)

Suprarenin was studied for use in conditions associated with acute or disruptive episodes, such as severe systemic allergic reactions. Due to the urgent nature of the condition, the evidence base is largely drawn from observational cohort studies and patient registries. These studies recorded patterns related to the timing of administration and outcomes describing episodic or acute changes in real-world settings.

Research also explored various administration methods and devices, such as auto-injectors. Studies monitored outcomes related to systemic or functional imbalance, which was observed in some studies. However, due to ethical constraints, the existing evidence for the medicine's role is largely derived from observational and physiological research. Evidence is limited regarding long-term outcomes or recovery status beyond the initial acute phase.

Evidence for Use in Cardiac Arrest and Circulatory Collapse

The research examining Suprarenin for acute systemic or functional imbalance consists of Systematic Reviews and Meta-analyses that consolidate findings from numerous trials and large patient registries. Studies examined outcomes monitoring physiological strain or stress, including metrics like the Return of Spontaneous Circulation (ROSC). Research also examined medium-term outcomes, such as measurements of survival to hospital discharge.

Studies examined temporary physiological imbalance and monitored acute changes in blood pressure for patients experiencing shock. Data show patterns related to measurements of ROSC and survival to hospital admission in the observed populations. However, when research examined survival with favorable neurological function, findings were mixed across different study groups. Data are still emerging regarding the overall outcome of neurological recovery.

Long-Term Studies and Follow-up Outcomes

Research has explored outcomes beyond the immediate acute crisis, particularly for patients surviving cardiac arrest. These studies monitored medium-term outcomes, such as survival rates to 30 days or up to measurements of survival to hospital discharge. However, the available data for sustained recovery and long-term quality of life are not fully established. Follow-up durations were often limited to the necessary period for acute stabilization, meaning that limited information exists on the durability of the initial physiological response.

Key Studies & References

  1. Epinephrine - StatPearls [Internet]
  2. Epinephrine Injection Drug Information - MedlinePlus
  3. Nebulized epinephrine for croup in children - Cochrane Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Suprarenin (FAQ)


Q: What conditions is Suprarenin officially approved to treat?

The active ingredient in Suprarenin is officially approved for providing rapid physiological support during acute crises. This includes the emergency treatment of severe, life-threatening allergic reactions (anaphylaxis) and for increasing dangerously low blood pressure (hypotension) in adults who are in septic shock.

Q: How quickly does Suprarenin begin to work after administration?

Official information indicates that the drug acts very quickly to restore vital functions. For its use in intensive care, the onset of a blood pressure increase can be seen in less than five minutes following intravenous administration. When given by intramuscular injection for an acute crisis, the drug is known for its rapid onset of action.

Q: Why does Suprarenin sometimes cause feelings of anxiety or shakiness?

Regulatory documents state that common side effects can include anxiety, restlessness, tremor, and shakiness. This occurs because the drug acts as a sympathomimetic agent, meaning it mimics the body's natural 'fight-or-flight' signals.

Q: What is the difference between the injection used in an emergency kit and the hospital infusion?

The two methods serve different purposes based on the clinical situation. The emergency kit is a fixed dose, given via an intramuscular or subcutaneous injection for immediate, short-term support during an acute crisis. Conversely, the hospital infusion is a highly diluted solution given continuously into a vein and is carefully adjusted for sustained life support.

Q: What are the signs that Suprarenin might be discolored or expired?

To support the product's effectiveness, regulatory standards suggest visual inspection before use. The product must be replaced if the solution appears cloudy, is discolored, or contains any solid particles. Additionally, the auto-injector should be discarded and replaced by the printed expiration date.

Q: Is Suprarenin effective for minor allergic reactions like hives or a mild rash?

Official indications state that the drug is for the emergency treatment of severe allergic reactions (anaphylaxis). While it impacts the entire system, its use is reserved for these life-threatening crises and it is not generally indicated for minor symptoms like a mild rash or hives.

Q: Why is it important not to delay using Suprarenin in an emergency?

Regulatory patient information emphasizes the urgency of immediate administration. This is because anaphylaxis, the severe allergic reaction that the drug treats, can progress rapidly and become life-threatening within a matter of minutes.

Q: Why is the self-injection route recommended over other methods in an emergency?

The administration guidelines specify the upper thigh (anterolateral aspect) for self-injection, as this route allows for effective absorption in an emergency. Administration into the buttocks is advised against, as it may be ineffective or lead to serious infection. Accidental injection into a vein (intravenously) is also a risk, as this can cause a dangerous and rapid increase in blood pressure.

Q: How long do the effects of Suprarenin last in the body?

The duration of the physiological effects is generally short. For example, when administered intravenously, the effects of the drug on blood pressure typically diminish within twenty minutes.

Q: Does Suprarenin interact with common over-the-counter medications?

The drug may interact with several categories of medicines, including some found over the counter. Official interaction warnings apply to Sympathomimetics and Antihistamines, which are common active ingredients in products used for cold, flu, and allergy relief.

Q: What does Suprarenin do to blood sugar levels?

According to official product information, Epinephrine may affect blood sugar levels. Its action can result in a state called hyperglycemia, or increased blood sugar, by encouraging the release of stored energy reserves in the body.

Q: Does using Suprarenin mean that I still need to go to the emergency room?

Using the medicine is not a substitute for professional care. Regulatory documents state that the drug is intended only as emergency supportive therapy, and official guidance indicates patients must still seek immediate medical or hospital attention after administering the injection.

Q: Why is Suprarenin sometimes administered through clothing?

Administration instructions permit the injection to be given into the anterolateral aspect of the thigh, through clothing, if necessary. This allowance is made to support the goal of immediate administration during a life-threatening emergency.

Q: Can people with diabetes use Suprarenin safely?

Official regulatory warnings indicate the drug should be administered with caution to patients with diabetes. This is due to the documented risk that the medicine may cause or worsen high blood sugar levels (hyperglycemia).

Q: Does Suprarenin interact with common cold or flu medications?

Official documents indicate potential interactions with certain types of cold and flu medications. Specifically, they list Sympathomimetic agents and Antihistamines, which are frequently used to treat cold symptoms, as having the potential to interact with Suprarenin.

Q: Why is Suprarenin available in different concentrations?

The different concentrations and volumes exist because the clinical situation strictly defines the required dosage and route. For example, a low volume, high-concentration fixed dose is needed for a rapid intramuscular injection, while a highly diluted solution is needed for a slow, continuous intravenous infusion in the hospital.

Q: Is it necessary to carry more than one dose of Suprarenin?

Regulatory guidance notes that patients are advised to have access to at least two auto-injectors. This is because official instructions indicate that a repeat injection may be necessary if severe symptoms of the allergic reaction continue or recur after the first dose.

Q: What is the reason for practicing with a 'trainer pen' for the injection device?

Official patient information states that a trainer pen is provided to allow patients and caregivers to practice. This is intended to help users become familiar with the technique and support confident use of the actual device accurately and quickly in an emergency situation.

Q: Are there any common food or drink items that interact with Suprarenin?

Based on regulatory-affiliated patient information, it is generally advised to avoid food and drinks containing high caffeine content. Official-affiliated patient information notes that patients may be advised to limit or avoid consumption of food and drinks with high caffeine content, as caffeine can enhance the cardiovascular effects of Epinephrine.

Q: Can a patient with an enlarged prostate use Suprarenin?

Regulatory documents advise that the drug should be used with caution in patients with an enlarged prostate, known as prostatic hyperplasia, especially if they experience urinary retention.

Q: What is the purpose of the sulfite preservative sometimes found in Suprarenin?

The active ingredient in the medicine is unstable and is highly susceptible to being oxidized, which reduces its potency. Sulfite is included as a preservative to stabilize the solution. Official warnings state that the presence of sulfite should not deter the drug's use in a life-threatening anaphylactic emergency.

Q: How long after using Suprarenin is the patient's heart rate monitored?

While the necessary duration of monitoring is determined by the treating healthcare professional, clinical protocols for related uses indicate that vital signs are often monitored for a minimum period of 5 minutes immediately following administration.

How should Suprarenin be stored and disposed of?

How to Store and Dispose of Suprarenin (Epinephrine)

Suprarenin must be stored according to official regulatory specifications to maintain its effectiveness.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (68°F–77°F or 20 C–25 C).
Prohibited Do not freeze or refrigerate. Do not expose to extreme heat or cold.
Protection Protect from light and keep in the original container to guard against damage.
Safety Keep the medication out of the sight and reach of children.

Disposal and Integrity

The solution must be visually inspected before use; replace the product if it is discolored, cloudy, or contains a precipitate. The auto-injector is a single-use device and must be discarded immediately after use. Any unused or expired product, including the sharp, must be disposed of in accordance with local requirements for medical sharps.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suprarenin found in:

A-Z Index: